CYP2D6 GENOTYPE DETERMINATION IN THE DANISH POPULATION

被引:39
|
作者
BROSEN, K [1 ]
NIELSEN, PN [1 ]
BRUSGAARD, K [1 ]
GRAM, LF [1 ]
SKJODT, K [1 ]
机构
[1] ODENSE UNIV,INST MED BIOL,DEPT MED MICROBIOL,DK-5000 ODENSE,DENMARK
关键词
SPARTEINE-OXIDATION; GENETIC POLYMORPHISM; CYP2D6; GENOTYPING; XBA1; RFLP-PCR; DANISH POPULATION;
D O I
10.1007/BF02570501
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
CYP2D6 genotyping was carried out by XbaI restriction fragment length polymorphism analysis and polymerase chain reaction in 168 healthy Danish volunteers, 77 extensive metabolizers (EM) and 91 poor metabolizers (PM) of sparteine. All EM were genotyped correctly as heterozygous or homozygous for the functional (wild type) gene, DG-wt. However, the DG-wt gene was apparently also present in 11 (12%) of the PM who accordingly were incorrectly genotyped as EM. The specificity of genotyping PM thus was 100% but the sensitivity was only 88%. The most common allele was the DG-wt with an apparent frequency of 0.741 (0.026) in the Danish population and the second most common allele was the D6-B with an apparent frequency of 0.194 (0.024). The median (range) of the sparteine metabolic ratio (MR) in 47 homozygous D6-wt EM was 0.28 (0.11-4.10) and the corresponding value in heterozygous EM was 0.36 (0.11-9.10). The median difference was 0.09 (95% confidence interval: 0.02-0.16). CYP2D6 phenotyping is a promising tool in tailoring the individual dose of tricyclic antidepressants, some neuroleplics and some antiarrhythmics. However if the genotype test could be improved with regard to both sensitivity in PM and the ability to predict CYP2D6 activity in EM then it would be of even greater clinical value in therapeutic drug monitoring.
引用
收藏
页码:221 / 225
页数:5
相关论文
共 50 条
  • [41] Impact of CYP2D6 Genotype on Paroxetine Serum Concentration
    Hole, Kristine
    Haslemo, Tore
    Molden, Espen
    THERAPEUTIC DRUG MONITORING, 2023, 45 (05) : 683 - 688
  • [42] Miotic action of tramadol is determined by CYP2D6 genotype
    Slanar, O.
    Nobilis, M.
    Kvetina, J.
    Mikoviny, R.
    Zima, T.
    Idle, J. R.
    Perlik, F.
    PHYSIOLOGICAL RESEARCH, 2007, 56 (01) : 129 - 136
  • [43] CYP2D6 genotype and the incidence of anal and vulvar cancer
    Chen, C
    Cook, LS
    Li, XY
    Hallagan, S
    Madeleine, MM
    Daling, JR
    Weiss, NS
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 1999, 8 (04) : 317 - 321
  • [44] CYP2D6 genotype and adverse drug reaction in the ICU
    Stamer, UM
    Bayerer, B
    Hoeft, A
    Stüber, F
    INTENSIVE CARE MEDICINE, 2003, 29 : S13 - S13
  • [45] COADMINISTRATION OF FLUVOXAMINE AND TOLPERISONE IN RELATION TO CYP2D6 GENOTYPE
    Kim, Y. H.
    Kim, S. H.
    Byeon, J. Y.
    Lee, H. J.
    Lee, Y.
    Lee, Y. J.
    Lee, S. Y.
    CLINICAL THERAPEUTICS, 2015, 37 (08) : E54 - E54
  • [46] Catalytic in vivo function of CYP2D6 in relation to the genotype
    Griese, EU
    Gaedigk, A
    Morike
    Mikus, G
    Zanger, U
    Eichelbaum, M
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1997, 355 (04) : 458 - 458
  • [47] CYP2D6 genotype and optimization of breast cancer treatment
    Bandres, F.
    Chicharro, L. M.
    Tejerina, A.
    del Saz, M.
    Fernaacutendez-Santander, A.
    EJC SUPPLEMENTS, 2010, 8 (03): : 179 - 179
  • [48] Impact of CYP2D6 genotype on postoperative tramadol analgesia
    Stamer, UM
    Lehnen, K
    Höthker, F
    Bayerer, B
    Wolf, S
    Hoeft, A
    Stuber, F
    PAIN, 2003, 105 (1-2) : 231 - 238
  • [49] Effect of the CYP2D6*10 Genotype on Tolterodine Pharmacokinetics
    Oishi, Masayo
    Chiba, Koji
    Malhotra, Bimal
    Suwa, Toshio
    DRUG METABOLISM AND DISPOSITION, 2010, 38 (09) : 1456 - 1463
  • [50] CYP2D6 genotype and phenotype relationship in South Indians
    Naveen, A. T.
    Prasanna, T.
    Farzana, B. L.
    Rajan, S.
    Adithan, C.
    JOURNAL OF POSTGRADUATE MEDICINE, 2006, 52 (04) : 253 - 256